Revenue	3 Months Ended
Mar. 31, 2022
Revenue From Contract With Customer [Abstract]
Revenue	5. Revenue Product revenue, net The Company currently operates in one reportable segment. There were no sales to customers outside of the United States during the three months ended March 31, 2022. The Company had one customer that individually comprised over 10% of product revenues, net for the three months ended March 31, 2022. Grant revenue and receivables NIH grant In May 2018, the Company was awarded a grant from the NIH for the Diagnostics via Rapid Enrichment, Identification, and Phenotypic Antibiotic Susceptibility Testing of Pathogens from Blood project. In April 2022, the Company exercised its fourth one-year option under the grant, extending the term through April 2023 with $1.1 million in additional funding available under the extension. During the three months ended March 31, 2022, the Company recognized $0.2 million of revenue related to this grant which was unbilled at March 31, 2022. During the three months ended March 31, 2021, no revenue was recognized related to this grant. NIH Rapid Acceleration of Diagnostics - RADx Initiative contracts In July 2020, the Company was awarded a subaward grant from the University of Massachusetts Medical School for Phase 1 of the NIH’s RADx initiative and a contract from the NIH directly for Phase 2 of the RADx initiative. The RADx initiative aims to speed the development, validation, and commercialization of innovative, rapid tests that can directly detect COVID-19. In 2021, the Company and the NIH amended the contract for the completion of the RADx initiative, extending the term of the contract to January 30, 2022 and decreased the potential milestone payment from $4.0 million to $2.0 million. The contract expired on January 30, 2022. During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.7 million and $7.0 million related to the RADx initiative, respectively.

Revenue

3 Months Ended

Mar. 31, 2022

Revenue From Contract With Customer [Abstract]

5. Revenue

Product revenue, net

The Company currently operates in one reportable segment. There were no sales to customers outside of the United States during the three months ended March 31, 2022. The Company had one customer that individually comprised over 10% of product revenues, net for the three months ended March 31, 2022.

Grant revenue and receivables

NIH grant

In May 2018, the Company was awarded a grant from the NIH for the Diagnostics via Rapid Enrichment, Identification, and Phenotypic Antibiotic Susceptibility Testing of Pathogens from Blood project. In April 2022, the Company exercised its fourth one-year option under the grant, extending the term through April 2023 with $1.1 million in additional funding available under the

extension. During the three months ended March 31, 2022, the Company recognized $0.2 million of revenue related to this grant which was unbilled at March 31, 2022. During the three months ended March 31, 2021, no revenue was recognized related to this grant.

NIH Rapid Acceleration of Diagnostics - RADx Initiative contracts

In July 2020, the Company was awarded a subaward grant from the University of Massachusetts Medical School for Phase 1 of the NIH’s RADx initiative and a contract from the NIH directly for Phase 2 of the RADx initiative. The RADx initiative aims to speed the development, validation, and commercialization of innovative, rapid tests that can directly detect COVID-19. In 2021, the Company and the NIH amended the contract for the completion of the RADx initiative, extending the term of the contract to January 30, 2022 and decreased the potential milestone payment from $4.0 million to $2.0 million. The contract expired on January 30, 2022. During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $0.7 million and $7.0 million related to the RADx initiative, respectively.